trying to kill cancer cells, destroy their "walls of protection" first.

The team, led by academics at the university, took samples of myeloid inhibition cells (MDSCs) from 200 newly diagnosed cancer patients, which can send out large chemical signals to shield tumor cells, causing the immune system and immunotherapy to fail to function and preventing T-cells that kill tumor cells from being activatedThe team found that in many types of cancer, a protein called CD33 is present on the surface of MDSCs, and an antibody drug already used to treat acute myeloid leukemia can work against CD33, eventually killing MDSCs and restoring the ability of T cells to attack tumor cells, according to the report, which is published in The Journal of BiomedicineDr Francis Moussey, one of the report's authors, said existing immunotherapy often failed to kill tumor cells because the immune system often failed to reach themNext, the team plans to validate the effectiveness and safety of this approach through clinical trials.